Cargando…

Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences

Checkpoint inhibitor (CPI) based immunotherapy (i.e., anit-CTLA-4/PD-1/PD-L1 antibodies) can effectively prolong overall survival of patients across several cancer types at the advanced stage. However, only part of patients experience objective responses from such treatments, illustrating large indi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yan, Xinyu, Zhang, Shouyue, Deng, Yun, Wang, Peiqi, Hou, Qianqian, Xu, Heng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6159743/ https://www.ncbi.nlm.nih.gov/pubmed/30294272 http://dx.doi.org/10.3389/fphar.2018.01050

Ejemplares similares

Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives
por: Liu, Zherui, et al.
Publicado: (2023)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

Updates in the Role of Checkpoint Inhibitor Immunotherapy in Classical Hodgkin’s Lymphoma
por: Nakhoda, Shazia, et al.
Publicado: (2022)

A novel nomogram and prognostic factor for metastatic renal cell carcinoma survival in the era of immune checkpoint inhibitors (ICIs)
por: Alradhi, Mohammed, et al.
Publicado: (2023)

The Role of ARID5B in Acute Lymphoblastic Leukemia and Beyond
por: Wang, Peiqi, et al.
Publicado: (2020)

Musculoskeletal adverse events induced by immune checkpoint inhibitors: a large-scale pharmacovigilance study
por: Liu, Hao, et al.
Publicado: (2023)

Development and Validation of a Prognostic Score for Hepatocellular Carcinoma Patients in Immune Checkpoint Inhibitors Therapies: The Hepatocellular Carcinoma Modified Gustave Roussy Immune Score
por: Li, Yongjiang, et al.
Publicado: (2022)

Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics
por: Twomey, Julianne D., et al.
Publicado: (2021)

Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies
por: Hradska, Katarina, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma
por: Chen, Xi, et al.
Publicado: (2022)

Clinical Insights Into Novel Immune Checkpoint Inhibitors
por: Lee, Jii Bum, et al.
Publicado: (2021)

Resistance to immune checkpoint inhibitors in gastric cancer
por: Liu, Kai, et al.
Publicado: (2023)

Risk Factors, Incidence, and Prognosis of Thromboembolism in Cancer Patients Treated With Immune Checkpoint Inhibitors
por: Zou, Xue-lin, et al.
Publicado: (2021)

In-situ formed thermosensitive hydrogel amplifies statin-mediated immune checkpoint blockade for coordinated tumor chemo-immunotherapy
por: Liu, Zefan, et al.
Publicado: (2023)

Immune checkpoint inhibitors combined with tyrosine kinase inhibitors or immunotherapy for treatment-naïve metastatic clear-cell renal cell carcinoma—A network meta-analysis. Focus on cabozantinib combined with nivolumab
por: Niewada, Maciej, et al.
Publicado: (2023)

Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors
por: Shen, Pan, et al.
Publicado: (2021)

Drug therapy for myocarditis induced by immune checkpoint inhibitors
por: Wu, Yihao, et al.
Publicado: (2023)

The correlation between probiotic use and outcomes of cancer patients treated with immune checkpoint inhibitors
por: Zhang, Lilong, et al.
Publicado: (2022)

How to Monitor Cardiac Complications of Immune Checkpoint Inhibitor Therapy
por: Spallarossa, Paolo, et al.
Publicado: (2020)

Neurologic Toxicity of Immune Checkpoint Inhibitors: A Review of Literature
por: Albarrán, Víctor, et al.
Publicado: (2022)

The Strategies and Mechanisms of Immune Checkpoint Inhibitors for Brain Metastases in NSCLC
por: Li, Ji, et al.
Publicado: (2022)

Immune checkpoint inhibitors in osteosarcoma: A hopeful and challenging future
por: Zhang, Zeng, et al.
Publicado: (2022)

Regulatory Network and Prognostic Effect Investigation of PIP4K2A in Leukemia and Solid Cancers
por: Zhang, Shouyue, et al.
Publicado: (2019)

Effects of PPIs use on clinical outcomes of urothelial cancer patients receiving immune checkpoint inhibitor therapy
por: Zhang, Lilong, et al.
Publicado: (2022)

Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management
por: Zhou, Yu-Wen, et al.
Publicado: (2019)

Safety and Efficacy of Therapeutic Cancer Vaccines Alone or in Combination With Immune Checkpoint Inhibitors in Cancer Treatment
por: Zhao, Jing, et al.
Publicado: (2019)

Understanding the functional inflammatory factors involved in therapeutic response to immune checkpoint inhibitors for pan-cancer
por: Wu, Yanmeizhi, et al.
Publicado: (2022)

Unleashing the efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma: factors, strategies, and ongoing trials
por: Yu, Jiahui, et al.
Publicado: (2023)

Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma
por: Wang, Di, et al.
Publicado: (2021)

Cardiotoxicity associated with immune checkpoint inhibitors: Current status and future challenges
por: Gan, Lu, et al.
Publicado: (2022)

Potential role of gut microbes in the efficacy and toxicity of immune checkpoints inhibitors
por: Ma, Jingxin, et al.
Publicado: (2023)

Incidence of Immune Checkpoint Inhibitor-Associated Diabetes: A Meta-Analysis of Randomized Controlled Studies
por: Lu, Jingli, et al.
Publicado: (2019)

PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
por: Alsaab, Hashem O., et al.
Publicado: (2017)

β-Glucan Combined With PD-1/PD-L1 Checkpoint Blockade for Immunotherapy in Patients With Advanced Cancer
por: Wang, Mengjie, et al.
Publicado: (2022)

Pulmonary Toxicities Associated With the Use of Immune Checkpoint Inhibitors: An Update From the Immuno-Oncology Subgroup of the Neutropenia, Infection & Myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer
por: Rapoport, Bernardo L., et al.
Publicado: (2021)

Editorial: Biomarkers of Immune-Checkpoint-Inhibitor Immunotherapies in Hepatocellular Carcinomas
por: Guo, Zhanjun, et al.
Publicado: (2022)

Suanzaoren Formulae for Insomnia: Updated Clinical Evidence and Possible Mechanisms
por: Zhou, Qi-Hui, et al.
Publicado: (2018)

Pan-Cancer Analysis Reveals Alternative Splicing Characteristics Associated With Immune-Related Adverse Events Elicited by Checkpoint Immunotherapy
por: He, Xiujing, et al.
Publicado: (2021)

A Review of Efficacy and Safety of Checkpoint Inhibitor for the Treatment of Acute Myeloid Leukemia
por: Liao, Dan, et al.
Publicado: (2019)

Hematological Side Effects of Immune Checkpoint Inhibitors: The Example of Immune-Related Thrombocytopenia
por: Calvo, Roser
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_dke5qr34b0s38ohk585k853r6r